Transforming life for patients with Parkinson’s disease

Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.

Two clinical phase II candidates

Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >

Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >

Proprietary technology platform

The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >

Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease.

Read more here >

Latest press release

IRLAB publishes interim report for July 1 – September 30, 2021

November 10, 2021 Regulatory

IRLAB today published its interim report for the third quarter 2021 (July 1 – September 30, 2021)

Read More >
Latest presentation

Earnings call Q3

November 10, 2021

Telco in connection with publication of quarterly report for the thrid quarter 2021 The presentation is available here (held in Swedish): https://tv.streamfabriken.com/irlab-q3-2021 To download the presentation as a pdf (in English), click here: IRLAB Q3 2021 presentation For more information Åsa Hillsten, Head of IR & Corporate Communications Telephone: +46 700 81 81 17 E-mail: […]

Read More >

Subscribe